AMGN

SEC source: 0001127602-21-011713 · form4.xml · nonDerivative · entry 1

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,017

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 63 RSUs which fully vest on 5/1/2021; 114 RSUs which vest in two installments of 56 on 4/27/2021 and 58 on 4/27/2022; 197 RSUs which vest in two installments of 65 on 5/3/2021 and 5/3/2022 and one installment of 67 on 5/3/2023; 169 RSUs which vest in installments of 55 on 5/5/2022, 56 on 5/5/2023 and 58 on 5/5/2024; and 1,453 RSUs which vest in two installments of 479 on 11/2/2022 and 11/2/2023 and one installment 495 on 11/2/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 56 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-011714 · form4.xml · nonDerivative · entry 1

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,565

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 642 RSUs which vest in installments of 316 on 4/27/2021 and 326 on 4/27/2022; 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023; and 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 234 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-21-011715 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,494

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,673 RSUs which vest on 5/1/2021; 335 RSUs which vest on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 8,597 RSUs which vest in installments of 4,234 on 11/2/2021 and 4,363 on 11/2/2022; 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,310 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-011716 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,044

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,171 RSUs which vest on 5/1/2021; 2,114 RSUs which vest in installments of 1,041 on 4/27/2021 and 1,073 on 4/27/2022; 3,947 RSUs which vest in installments of 1,302 on 5/3/2021, 1,303 on 5/3/2022 and 1,342 on 5/3/2023; and 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 660 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-010143 · form4.xml · derivative · entry 3

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 1,000 shares

Expires 2022-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-010143 · form4.xml · nonDerivative · entry 2

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,805

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

F2 · balance_after: These shares include 2,142 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-010143 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,805

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-009476 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 609,806

F1 · security: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,019 RSUs which vest on 5/1/2021; 9,439 RSUs which vest in installments of 4,649 on 4/27/2021 and 4,790 on 4/27/2022; 15,791 RSUs which vest in two installments of 5,211 on 5/3/2021 and 5/3/2022 and one installment of 5,369 on 5/3/2023; and 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,019 RSUs which vest on 5/1/2021; 9,439 RSUs which vest in installments of 4,649 on 4/27/2021 and 4,790 on 4/27/2022; 15,791 RSUs which vest in two installments of 5,211 on 5/3/2021 and 5/3/2022 and one installment of 5,369 on 5/3/2023; and 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 2,382 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-009477 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,159

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 10,263 RSUs which vest on 11/2/2021; 4,511 RSUs which vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,045 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-009478 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,670

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,046 which will vest on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; and 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 838 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-009479 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,401

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 159 RSUs which fully vest on 5/1/2021; 302 RSUs which vest in installments of 149 on 4/27/2021 and 153 on 4/27/2022; 452 RSUs which vest in two installments of 149 on 5/3/2021 and 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; and 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 185 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-009480 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,682

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 670 RSUs which vest on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023; and 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 561 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-009481 · form4.xml · nonDerivative · entry 1

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,113

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 63 RSUs which fully vest on 5/1/2021; 114 RSUs which vest in two installments of 56 on 4/27/2021 and 58 on 4/27/2022; 197 RSUs which vest in two installments of 65 on 5/3/2021 and 5/3/2022 and one installment of 67 on 5/3/2023; 169 RSUs which vest in installments of 55 on 5/5/2022, 56 on 5/5/2023 and 58 on 5/5/2024; and 1,453 RSUs which vest in two installments of 479 on 11/2/2022 and 11/2/2023 and one installment 495 on 11/2/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 40 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-009482 · form4.xml · nonDerivative · entry 1

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,504

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 642 RSUs which vest in installments of 316 on 4/27/2021 and 326 on 4/27/2022; 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023; and 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 202 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-21-009483 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,715

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,673 RSUs which vest on 5/1/2021; 335 RSUs which vest on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 8,597 RSUs which vest in installments of 4,234 on 11/2/2021 and 4,363 on 11/2/2022; 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,152 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-009484 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,251

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,171 RSUs which vest on 5/1/2021; 2,114 RSUs which vest in installments of 1,041 on 4/27/2021 and 1,073 on 4/27/2022; 3,947 RSUs which vest in installments of 1,302 on 5/3/2021, 1,303 on 5/3/2022 and 1,342 on 5/3/2023; and 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 574 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-007182 · form4.xml · derivative · entry 3

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 73,500 shares

Expires 2021-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-007182 · form4.xml · nonDerivative · entry 2

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 570,853

F1 · balance_after: Non-market exercise of a total of 73,500 stock options expiring April 25, 2021 wherein 47,527 shares, in the aggregate, issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 5,019 RSUs which vest on 5/1/2021; 9,439 RSUs which vest in installments of 4,649 on 4/27/2021 and 4,790 on 4/27/2022; 15,791 RSUs which vest in two installments of 5,211 on 5/3/2021 and 5/3/2022 and one installment of 5,369 on 5/3/2023; and 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 2,382 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-007182 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 618,380

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-006060 · form4.xml · derivative · entry 3

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,300 shares

Expires 2021-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-006060 · form4.xml · nonDerivative · entry 2

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,912

F1 · balance_after: Non-market exercise of 2,300 stock options expiring April 25, 2021 wherein 1,147 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,673 RSUs which vest on 5/1/2021; 335 RSUs which vest on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 8,597 RSUs which vest in installments of 4,234 on 11/2/2021 and 4,363 on 11/2/2022; 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 1,152 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-006060 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,059

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-005058 · form4.xml · derivative · entry 3

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 1,000 shares

Expires 2022-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-005058 · form4.xml · nonDerivative · entry 2

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,805

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

F2 · balance_after: These shares include 2,142 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-005058 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,805

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-004470 · form4.xml · nonDerivative · entry 1

Williams R Sanders · CIK 0001375347 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,659

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

SEC source: 0001127602-21-004798 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,074

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 670 RSUs which vest on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023; and 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 561 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-004468 · form4.xml · nonDerivative · entry 1

Kullman Ellen Jamison · CIK 0001303141 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,907.9979

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vest immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the deferral schedule.

F2 · balance_after: These shares include 381 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-004257 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,945

F1 · price: The price reported is an average price. Full information regarding the number of shares sold at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,046 which will vest on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; and 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 838 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-001691 · form4.xml · derivative · entry 3

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 1,000 shares

Expires 2022-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-001691 · form4.xml · nonDerivative · entry 2

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,805

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

F2 · balance_after: These shares include 2,142 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-001691 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,805

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-028671 · form4.xml · nonDerivative · entry 1

Williams R Sanders · CIK 0001375347 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,909

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

SEC source: 0001127602-20-028203 · form4.xml · nonDerivative · entry 1

Kullman Ellen Jamison · CIK 0001303141 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,846.0717

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vest immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the deferral schedule.

F2 · balance_after: These shares include 336 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-028204 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,036

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 10,263 RSUs which vest on 11/2/2021; 4,511 RSUs which vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 911 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-028205 · form4.xml · nonDerivative · entry 1

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,632

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 63 RSUs which fully vest on 5/1/2021; 114 RSUs which vest in two installments of 56 on 4/27/2021 and 58 on 4/27/2022; 197 RSUs which vest in two installments of 65 on 5/3/2021 and 5/3/2022 and one installment of 67 on 5/3/2023; 169 RSUs which vest in installments of 55 on 5/5/2022, 56 on 5/5/2023 and 58 on 5/5/2024; and 1,453 RSUs which vest in two installments of 479 on 11/2/2022 and 11/2/2023 and one installment 495 on 11/2/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 26 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-028206 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,619

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,673 RSUs which vest on 5/1/2021; 335 RSUs which vest on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 8,597 RSUs which vest in installments of 4,234 on 11/2/2021 and 4,363 on 11/2/2022; 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,012 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-023922 · form4.xml · derivative · entry 3

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 1,000 shares

Expires 2021-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-023922 · form4.xml · nonDerivative · entry 2

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,589

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

F2 · balance_after: These shares include 1,926 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-023922 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-023285 · form4.xml · nonDerivative · entry 1

Williams R Sanders · CIK 0001375347 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,159

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

SEC source: 0001127602-20-022624 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,026

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 159 RSUs which fully vest on 5/1/2021; 302 RSUs which vest in installments of 149 on 4/27/2021 and 153 on 4/27/2022; 452 RSUs which vest in two installments of 149 on 5/3/2021 and 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; and 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 55 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-022626 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,376

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,171 RSUs which vest on 5/1/2021; 2,114 RSUs which vest in installments of 1,041 on 4/27/2021 and 1,073 on 4/27/2022; 3,947 RSUs which vest in installments of 1,302 on 5/3/2021, 1,303 on 5/3/2022 and 1,342 on 5/3/2023; and 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 424 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-022622 · form4.xml · nonDerivative · entry 1

Kullman Ellen Jamison · CIK 0001303141 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,663.297

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vest immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the deferral schedule.

F2 · balance_after: These shares include 294 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-022623 · form4.xml · nonDerivative · entry 1

MILES AMY E · CIK 0001248617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 408

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

SEC source: 0001127602-20-022624 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,316

SEC source: 0001127602-20-022000 · form4.xml · derivative · entry 3

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 1,000 shares

Expires 2021-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-022000 · form4.xml · nonDerivative · entry 2

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,589

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

F2 · balance_after: These shares include 1,926 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-022000 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-019949 · form4.xml · derivative · entry 3

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 1,000 shares

Expires 2021-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.